All In Biotech

Drug Trial Radar · NCT04265755

Biomarker and Genetic Predictors of Erenumab Treatment Response

Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)

Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,406

Actual

Start

Oct 26, 2020

Primary completion

Jan 18, 2023

Study completion Jan 18, 2023

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the relationship between clinical response to erenumab and genetic biomarkers

Conditions

  • Migraine

Interventions

  • ErenumabDrug

    Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRSTime frame: 4-week Baseline Period and the last 3 months (Months 4, 5, and 6) of the 24-week Open-label Treatment Period

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Glostrup Hospital

    Glostrup Municipality, Denmark

  • Thjonustumidstod Rannsoknaverkefna

    Reykjavik, Iceland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.